Daiichi Sankyo, Esperion Report Swissmedic Approval For NILEMDO & NUSTENDI

(RTTNews) - Daiichi Sankyo Europe GmbH (DSKYF.PK) and Esperion Therapeutics (ESPR) announced Swissmedic approval for NILEMDO tablet and NUSTENDI tablet, for people with high low-density lipoprotein cholesterol in Switzerland. NILEMDO (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients.

Lucas Schalch, Country Manager at Daiichi Sankyo Switzerland, said: "Today's approval of NILEMDO and NUSTENDI is a pivotal milestone for patients in secondary prevention, offering them new, convenient treatment options and demonstrating another step forward in our commitment to reduce the risk of atherosclerotic cardiovascular disease."